VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
0.2860
+0.0085 (3.06%)
At close: Aug 21, 2026, 4:00 PM EDT
0.2737
-0.0123 (-4.30%)
After-hours: Aug 21, 2026, 7:59 PM EDT
VivoSim Labs Employees
As of June 30, 2026, VivoSim Labs had 15 total employees, including 9 full-time and 6 part-time employees. The number of employees did not change since the number was last reported on March 31, 2026.
Employees
15
Change
n/a
Growth
n/a
Revenue / Employee
$7,467
Profits / Employee
-$822,533
Market Cap
4.25M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 15 | 0 | - | 15 | 0 |
| Mar 31, 2026 | 15 | 2 | 15.38% | 9 | 6 |
| Mar 31, 2025 | 13 | -7 | -35.00% | 5 | 8 |
| Mar 31, 2024 | 20 | -4 | -16.67% | 12 | 8 |
| Mar 31, 2023 | 24 | 6 | 33.33% | 15 | 9 |
| Mar 31, 2022 | 18 | 9 | 100.00% | 9 | 9 |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Aptevo Therapeutics | 33 |
| GeoVax Labs | 19 |
| Revelation Biosciences | 9 |
| Galmed Pharmaceuticals | 6 |
| Jupiter Neurosciences | 5 |
| Mustang Bio | 4 |
| GRI Bio | 4 |
VIVS News
- 17 days ago - VivoSim Provides Financial and Listing Compliance Update - GlobeNewsWire
- 4 weeks ago - VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services - GlobeNewsWire
- 5 weeks ago - VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor - GlobeNewsWire
- 5 weeks ago - VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 - GlobeNewsWire
- 7 weeks ago - VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting - GlobeNewsWire
- 4 months ago - VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing - GlobeNewsWire
- 5 months ago - VivoSim Announces Pricing of up to a $4 Million Public Offering - GlobeNewsWire
- 5 months ago - VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - GlobeNewsWire